4//SEC Filing
Derakhshan Behrad 4
Accession 0001562180-24-001226
CIK 0001710072other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 5:42 PM ET
Size
20.3 KB
Accession
0001562180-24-001226
Insider Transaction Report
Form 4
Derakhshan Behrad
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-08$1.93/sh+4,600$8,878→ 11,620 total - Exercise/Conversion
Common Stock
2024-02-09$1.93/sh+4,800$9,264→ 11,820 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-07−600→ 154,417 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (600 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-08−4,600→ 149,817 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (4,600 underlying) - Sale
Common Stock
2024-02-08$20.01/sh−4,600$92,049→ 7,020 total - Sale
Common Stock
2024-02-09$20.04/sh−4,800$96,209→ 7,020 total - Exercise/Conversion
Common Stock
2024-02-07$1.93/sh+600$1,158→ 7,620 total - Sale
Common Stock
2024-02-07$20.00/sh−600$12,000→ 7,020 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-09−4,800→ 145,017 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (4,800 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023.
- [F2]Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
Documents
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001853109
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 5:42 PM ET
- Size
- 20.3 KB